Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.
Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Sci Rep. 2017 06 02; 7(1):2707.
-
Animals
-
Antibodies, Blocking
-
Central Nervous System
-
Chemokine CCL2
-
Dendritic Cells
-
Encephalomyelitis, Autoimmune, Experimental
-
Endothelium, Vascular
-
Immunity
-
Lectins
-
Lectins, C-Type
-
Mice
-
Mice, Knockout
-
Models, Biological
-
Myeloid Cells
-
Phenotype
-
Protein Binding
-
Protein Tyrosine Phosphatase, Non-Receptor Type 11
-
Protein Tyrosine Phosphatase, Non-Receptor Type 6
-
Receptors, Mitogen
-
Recurrence
-
Severity of Illness Index
-
Signal Transduction
-
Transendothelial and Transepithelial Migration